Kedrion Biopharma joins IPOPI in supporting patients with APP PID Genius

Kedrion Biopharma has been proudly supporting IPOPI, the International Patient Organisation for Primary Immunodeficiencies, in designing, developing and launching PID Genius, the first mobile application developed by a patient organization for people living with PIDs the world over.

PID GENIUS is the personal assistant to PID patients in search of an easy and dynamic way of keeping track of their treatments, day-to-day symptoms, vaccinations, contacts, and most important documents. PID GENIUS also offers the possibility of displaying stored information in dashboards, facilitating discussions between patients and their medical specialists. “We hope that with this mobile application, people living with PIDs will see the management of their day-to-day life and treatment become simpler and easier to follow up, sparing them the trouble of managing with a big bulk of files”, said Jose Drabwell, from IPOPI.

IPOPI has developed PID GENIUS with a view of helping people living with primary immunodeficiencies, a group of around 300 rare and chronic diseases caused when some components of the immune system (mainly cells and proteins) do not work properly. Due to the specificities of these diseases, people living with PIDs need lifelong treatment (immunoglobulin replacement therapies in most cases, but also antibiotics, interferon-gamma, growth factor and others) as well as to consult with a wide range of specialists. PID GENIUS will help them organise all the information they need and make it available at any time, including in case of emergency.

Kedrion Biopharma is an IPOPI longstanding partner in its goal of advancing disease awareness and access to care for all PID patients worldwide. The mobile APP PID GENIUS, just launched at the IPIC Congress in Dubai and already available for free download for Android and iOS, is the latest initiative developed together. “For us, innovation means contributing, every day, to improve the quality of life of people living with Primary Immunodeficiencies and other rare diseases”, Ferdinando Borgese, Regional Commercial Director Asia, Middle East & Africa at Kedrion Biopharma stated. “Through our local partners, we strive to broaden access to plasma-derived therapies. At a global level, we cooperate with IPOPI to raise disease awareness and patient care. PID GENIUS will help us to make a difference in this.”

Learn more about IPOPI at

For more information please contact: [email protected]
error: Content is protected !!